Comparison of ticagrelor and prasugrel just before PCI in NSTE
acute coronary syndromes, LIKE-ACCOAST analysis

a 2023

Comparison of ticagrelor and prasugrel just before PCI in NSTE acute coronary syndromes, LIKE-ACCOAST analysis

MOTOVSKA, Z., Jiří JARKOVSKÝ, A. KOVARIK, J. MROZEK, Ota HLINOMAZ et. al.

Basic information

Original name

Comparison of ticagrelor and prasugrel just before PCI in NSTE acute coronary syndromes, LIKE-ACCOAST analysis

Authors

MOTOVSKA, Z. (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), A. KOVARIK (203 Czech Republic), J. MROZEK (203 Czech Republic), Ota HLINOMAZ (203 Czech Republic), J. PRECEK (203 Czech Republic), M. HROMADKA (203 Czech Republic), A. ZOHOR (203 Czech Republic), Petr KALA (203 Czech Republic, belonging to the institution), P. TOMASOV (203 Czech Republic), P. CERVINKA (203 Czech Republic), J. MATEJKA (203 Czech Republic), Klára BENEŠOVÁ (203 Czech Republic) and S. DRABKOVA (203 Czech Republic)

Edition

ESC Congress 2023 25-28 August 2023 Amsterdam, Netherlands, 2023

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 39.300 in 2022

RIV identification code

RIV/00216224:14110/23:00133231

Organization unit

Faculty of Medicine

ISSN

DOI

http://dx.doi.org/10.1093/eurheartj/ehad655.1493

Keywords (in Czech)

ticagrelor; NSTE ACS; prasugrel; acute coronary syndromes

Keywords in English

ticagrelor; NSTE ACS; prasugrel; acute coronary syndromes

Abstract

V originále

Recommendations for the preference of prasugrel over ticagrelor just before PCI in NSTE ACS are based on limited and controversial evidence. Furthermore, prasugrel can’t be used in patients after a stroke/TIA, and the risk of bleeding in older and low-weight patients annuls its benefit. Purpose We aimed to add to the current evidence comparing the benefit of prasugrel and ticagrelor just before PCI (without pretreatment) in NSTE ACS patients.

Links

90249, large research infrastructures

Name: CZECRIN IV

Citovat

MOTOVSKA, Z., Jiří JARKOVSKÝ, A. KOVARIK, J. MROZEK, Ota HLINOMAZ, J. PRECEK, M. HROMADKA, A. ZOHOR, Petr KALA, P. TOMASOV, P. CERVINKA, J. MATEJKA, Klára BENEŠOVÁ and S. DRABKOVA. Comparison of ticagrelor and prasugrel just before PCI in NSTE acute coronary syndromes, LIKE-ACCOAST analysis. In ESC Congress 2023 25-28 August 2023 Amsterdam, Netherlands. 2023. ISSN 0195-668X. Available from: https://dx.doi.org/10.1093/eurheartj/ehad655.1493.

@proceedings{2365651,
   author = {Motovska, Z. and Jarkovský, Jiří and Kovarik, A. and Mrozek, J. and Hlinomaz, Ota and Precek, J. and Hromadka, M. and Zohor, A. and Kala, Petr and Tomasov, P. and Cervinka, P. and Matejka, J. and Benešová, Klára and Drabkova, S.},
   booktitle = {ESC Congress 2023 25-28 August 2023 Amsterdam, Netherlands},
   doi = {http://dx.doi.org/10.1093/eurheartj/ehad655.1493},
   keywords = {ticagrelor; NSTE ACS; prasugrel; acute coronary syndromes},
   language = {eng},
   title = {Comparison of ticagrelor and prasugrel just before PCI in NSTE acute coronary syndromes, LIKE-ACCOAST analysis},
   url = {https://academic.oup.com/eurheartj/article/44/Supplement_2/ehad655.1493/7391067},
   year = {2023}
}

TY  - CONF
ID  - 2365651
AU  - Motovska, Z. - Jarkovský, Jiří - Kovarik, A. - Mrozek, J. - Hlinomaz, Ota - Precek, J. - Hromadka, M. - Zohor, A. - Kala, Petr - Tomasov, P. - Cervinka, P. - Matejka, J. - Benešová, Klára - Drabkova, S.
PY  - 2023
TI  - Comparison of ticagrelor and prasugrel just before PCI in NSTE acute coronary syndromes, LIKE-ACCOAST analysis
KW  - ticagrelor
KW  - NSTE ACS
KW  - prasugrel
KW  - acute coronary syndromes
UR  - https://academic.oup.com/eurheartj/article/44/Supplement_2/ehad655.1493/7391067
N2  - Recommendations for the preference of prasugrel over ticagrelor just before PCI in NSTE ACS are based on limited and controversial evidence. Furthermore, prasugrel can’t be used in patients after a stroke/TIA, and the risk of bleeding in older and low-weight patients annuls its benefit. Purpose We aimed to add to the current evidence comparing the benefit of prasugrel and ticagrelor just before PCI (without pretreatment) in NSTE ACS patients.
ER  -

MOTOVSKA, Z., Jiří JARKOVSKÝ, A. KOVARIK, J. MROZEK, Ota HLINOMAZ, J. PRECEK, M. HROMADKA, A. ZOHOR, Petr KALA, P. TOMASOV, P. CERVINKA, J. MATEJKA, Klára BENEŠOVÁ and S. DRABKOVA. Comparison of ticagrelor and prasugrel just before PCI in NSTE acute coronary syndromes, LIKE-ACCOAST analysis. In \textit{ESC Congress 2023 25-28 August 2023 Amsterdam, Netherlands}. 2023. ISSN~0195-668X. Available from: https://dx.doi.org/10.1093/eurheartj/ehad655.1493.

Detailed Information on Publication Record